IC 41

Drug Profile

IC 41

Alternative Names: HCV vaccine - Intercell; Hepatitis C virus vaccine - Intercell; IC41

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Intercell
  • Class Viral hepatitis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 21 May 2012 No development reported - Phase-II for Hepatitis C in Germany (Intradermal)
  • 21 May 2012 No development reported - Phase-II for Hepatitis C in Poland (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top